MindMed to Host Conference Call and Webcast to Discuss Data Update for MM120

Contributed by: Business Wire

Logo

Tags

Research

Mental Health

Neurology

Clinical Trials

Biotechnology

General Health

Pharmaceutical

Health

Science

Other Science

MindMed

More Like This

MindMed Announces Constructive End-of-Phase 2 Meeting with U.S. FDA for MM120 in Generalized Anxiety Disorder (GAD)

MindMed Receives FDA Breakthrough Therapy Designation and Announces Positive 12-Week Durability Data From Phase 2B Study of MM120 for Generalized Anxiety Disorder

MindMed Announces Business Update and Anticipated Milestones for 2024

MindMed Reports 2023 Financial Results and Business Updates

MindMed Reports First Quarter 2024 Financial Results and Business Updates

MindMed Presents Phase 2b Study of MM120 for Generalized Anxiety Disorder (GAD) at American Psychiatric Association (APA) Annual Meeting in New York

MindMed Reports Second Quarter 2024 Financial Results and Business Updates

MindMed Announces Issuance of New Patent for MM120 Orally Disintegrating Tablet (ODT)